Volume 63, Issue 3, Pages 462-472 (March 2013) Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance Jorg Oddens, Maurizio Brausi, Richard Sylvester, Aldo Bono, Cees van de Beek, George van Andel, Paolo Gontero, Wolfgang Hoeltl, Levent Turkeri, Sandrine Marreaud, Sandra Collette, Willem Oosterlinck European Urology Volume 63, Issue 3, Pages 462-472 (March 2013) DOI: 10.1016/j.eururo.2012.10.039 Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 1 Consolidated Standards of Reporting Trials diagram. FD=full dose; ITT=intention to treat. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 2 Disease-free interval by treatment group. BCG=bacillus Calmette-Guérin; df=degrees of freedom; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 3 Disease-free interval: one-third dose versus full dose. BCG=bacillus Calmette-Guérin; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 4 Disease-free interval: 1 yr of maintenance versus 3 yr of maintenance. BCG=bacillus Calmette-Guérin; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 5 Disease-free interval: 1 yr of maintenance versus 3 yr of maintenance according to dose and risk group. HR=hazard ratio; CI=confidence interval; df=degrees of freedom. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 6 Time to progression by treatment group. BCG=bacillus Calmette-Guérin; df=degrees of freedom; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions
Fig. 7 Duration of survival by treatment group. BCG=bacillus Calmette-Guérin; df=degrees of freedom; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions